Latest news
BIAF: Strong CyPath® Lung growth drives Q2 2026, but liquidity concerns persist amid ongoing losses - TradingViewTradingView · Fri, 07 Aug 2026 20:49:59 GMTBIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss - TradingViewTradingView · Fri, 07 Aug 2026 12:36:27 GMTbioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingViewTradingView · Fri, 07 Aug 2026 12:33:01 GMTPhysician offices ordering bioAffinity's lung test rose 122% in Q2 - Stock TitanStock Titan · Fri, 07 Aug 2026 12:00:00 GMTPress Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung - MoomooMoomoo · Fri, 07 Aug 2026 12:00:00 GMTbioAffinity Technologies Highlights CyPath Lung Clinical Framework - TipRanksTipRanks · Mon, 27 Jul 2026 13:11:45 GMTbioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT